Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 1
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` UNITED STATES INTERNATIONAL TRADE COMMISSION
`
` WASHINGTON, D.C.
`
` - - - - - - - - - - - - - - - X
`
` In the Matter of :
`
` :
`
` CERTAIN PRE-FILLED SYRINGES : Investigation No.
`
` FOR INTRAVITREAL INJECTION : 337-TA-1207
`
` AND COMPONENTS THEREOF :
`
` - - - - - - - - - - - - - - - X
`
` Remote Deposition
`
` Friday, December 4, 2020
`
` CONFIDENTIAL BUSINESS INFORMATION - SUBJECT TO
`
` PROTECTIVE ORDER
`
` Videotaped deposition of CHRISTOPHER SIMMS
`
`in his personal capacity and as 30(b)(6) witness for
`
`Novartis, called for examination by counsel for
`
`Respondent Regeneron in the above-entitled matter,
`
`pursuant to notice, the witness being duly sworn by
`
`MARY GRACE CASTLEBERRY, a Notary Public in and for
`
`the District of Columbia, taken at 8:58 a.m. EST,
`
`Friday, December 4, 2020, and the proceedings being
`
`taken down by Stenotype by MARY GRACE CASTLEBERRY,
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 1
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` UNITED STATES INTERNATIONAL TRADE COMMISSION
`
` WASHINGTON, D.C.
`
` - - - - - - - - - - - - - - - X
`
` In the Matter of :
`
` :
`
` CERTAIN PRE-FILLED SYRINGES : Investigation No.
`
` FOR INTRAVITREAL INJECTION : 337-TA-1207
`
` AND COMPONENTS THEREOF :
`
` - - - - - - - - - - - - - - - X
`
` Remote Deposition
`
` Friday, December 4, 2020
`
` CONFIDENTIAL BUSINESS INFORMATION - SUBJECT TO
`
` PROTECTIVE ORDER
`
` Videotaped deposition of CHRISTOPHER SIMMS
`
`in his personal capacity and as 30(b)(6) witness for
`
`Novartis, called for examination by counsel for
`
`Respondent Regeneron in the above-entitled matter,
`
`pursuant to notice, the witness being duly sworn by
`
`MARY GRACE CASTLEBERRY, a Notary Public in and for
`
`the District of Columbia, taken at 8:58 a.m. EST,
`
`Friday, December 4, 2020, and the proceedings being
`
`taken down by Stenotype by MARY GRACE CASTLEBERRY,
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 2
`
`RPR, and transcribed under her direction.
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 3
`
`APPEARANCES:
`
` On behalf of the Complainants Novartis Pharma
`
` AG, Novartis Pharmaceuticals Corporation,
`
` Novartis Technology LLC:
`
` MARK G. DAVIS, ESQ.
`
` Goodwin Procter
`
` The New York Times Building
`
` 620 Eighth Avenue
`
` New York, New York 10018-1405
`
` (212) 813-8800
`
` On behalf of Respondent Regeneron
`
` Pharmaceuticals, Inc.:
`
` PRIYATA Y. PATEL, ESQ.
`
` ROBERT T. VLASIS, III, ESQ.
`
` Weil Gotshal & Manges
`
` 2001 M Street, N.W., Suite 600
`
` Washington, D.C. 20036
`
` (202) 682-7000
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 4
`
`APPEARANCES (Continued):
`
` On behalf of the International Trade Commission:
`
` W. PETER GUARNIERI, ESQ.
`
` Investigative Attorney
`
` Office of Unfair Import Investigations
`
` U.S. International Trade Commission
`
` 500 E Street, S.W.
`
` Washington, D.C. 20436
`
` (202) 708-1525
`
` ALSO PRESENT:
`
` JASON AQUI, Videographer
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 5
`
` C O N T E N T S
`
`WITNESS EXAMINATION BY COUNSEL FOR
`
`CHRISTOPHER SIMMS REGENERON ITC
`
` BY MS. PATEL 7
`
` BY MR. GUANIERI 90
`
` BY MS. PATEL 94
`
` E X H I B I T S
`
`EXHIBIT NO. PAGE
`
`1 - Notice of Deposition 10
`
`2 - LinkedIn profile of Christopher Simms 16
`
`3 - Declaration of Christopher Simms 22
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 6
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` P R O C E E D I N G S
`
` THE VIDEOGRAPHER: We are now on the
`
`record in the matter of Certain Prefilled Syringes
`
`for Intravitreal Injection and Components Thereof.
`
`Today's date is December 4th, 2020. The time on the
`
`video monitor is 8:58 a.m. Eastern Standard Time.
`
` This is the video recorded deposition of
`
`Chris Simms being taken virtually. I'm the camera
`
`operator. My name is Jason Aqui in association with
`
`TrustPoint/Alderson Reporting. The court reporter is
`
`Mary Grace Castleberry also in association with
`
`TrustPoint/Alderson Reporting.
`
` Will all attorneys please identify
`
`themselves and the parties they represent beginning
`
`with the party noticing this proceeding.
`
` MS. PATEL: Good morning. This is Priya
`
`Patel from Weil Gotshal & Manges in Washington, D.C.
`
`representing respondent, Regeneron Pharmaceuticals,
`
`Inc. Also with me today is Robert Vlasis also on
`
`behalf of respondent.
`
` MR. DAVIS: Hi. Mark Davis of Goodwin
`
`Procter on behalf of the complainant, Novartis, and
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.006
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 7
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`the witness, Christopher Simms.
`
` MR. GUARNIERI: And this is Pete Guarnieri
`
`from the Office of Unfair Import Investigations at
`
`the U.S. International Trade Commission.
`
` THE VIDEOGRAPHER: Will the court reporter
`
`please administer the oath.
`
`Whereupon,
`
` CHRISTOPHER SIMMS,
`
`was called as a witness by counsel for Respondent
`
`Regeneron, and having been duly sworn by the Notary
`
`Public, was examined and testified as follows:
`
` EXAMINATION BY COUNSEL FOR RESPONDENT REGENERON
`
`BY MS. PATEL:
`
` Q. Good morning, Mr. Simms.
`
` A. Good morning. How are you?
`
` Q. Good. How are you?
`
` A. Good.
`
` Q. Could you please state your name and
`
`address for the record.
`
` A. Christopher Simms. My address is Madison,
`
`New Jersey. Do you want my full address or just the
`
`town?
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.007
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 17
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. Is this your LinkedIn profile?
`
` A. It's an abbreviated version of my LinkedIn
`
`profile, yes.
`
` Q. So is this not a complete and accurate
`
`representation of your professional and education --
`
`educational background?
`
` MR. DAVIS: Object to form.
`
` THE WITNESS: It's an accurate
`
`representation. The full profile contains more
`
`detail, but it's an accurate representation. The
`
`information contained here is accurate.
`
`BY MS. PATEL:
`
` Q. Okay. Well, let's start with your current
`
`position in Novartis. What is your current title?
`
` A. As shown here, my current title is I'm the
`
`vice president of the U.S. ophthalmics franchise.
`
` Q. And is that -- what's represented here is
`
`what your current title is, is that correct, just to
`
`confirm?
`
` A. Yes.
`
` MR. DAVIS: Object to form.
`
`BY MS. PATEL:
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.008
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 18
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. How long have you held this position?
`
` A. Since April this year, April 2020. So
`
`seven, eight months.
`
` Q. Okay. What are your responsibilities in
`
`this position?
`
` A. I'm responsible for the commercial
`
`activities for our ophthalmics medicines portfolio.
`
`That includes the two primary brands of BEOVU and
`
`Xiidra.
`
` Q. BEOVU and what was the second one?
`
` A. Xiidra. X-i-i-d-r-a.
`
` Q. And when you say BEOVU, do you mean BEOVU
`
`in the vial presentation or BEOVU in the PFS
`
`presentation or both?
`
` MR. DAVIS: Object to form.
`
` THE WITNESS: I mean BEOVU the brand,
`
`which includes both presentations.
`
`BY MS. PATEL:
`
` Q. What are the groups that you oversee in
`
`your position?
`
` A. I oversee a sales and marketing team for
`
`BEOVU, that supports BEOVU. I also oversee a sales
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.009
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 26
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`is that right?
`
` A. That's correct.
`
` Q. What is your understanding of that based
`
`on?
`
` A. It's based on two factors primarily. One
`
`is feedback from physicians indicating a preference
`
`for a prefilled syringe format. It's also based upon
`
`the observed rate of conversion from the launch of a
`
`prefilled syringe in this particular therapeutic area
`
`a couple of years prior.
`
` Q. Is it your understanding that the
`
`prefilled syringe format is preferable over the vial
`
`format?
`
` A. When -- sorry. Can you clarify, when you
`
`say preferable, who are you referring to who has that
`
`preference?
`
` Q. Providers, customers.
`
` A. Thank you. Yes.
`
` MR. DAVIS: Objection. Compound.
`
`BY MS. PATEL:
`
` Q. When you say that your prior understanding
`
`informs why you think there will be a rapid
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.0010
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 73
`
`I
`
`
`I
`
`
`I
`
`
`I
`
`
`I
`
`
`I
`
`
`I
`
`
`I
`
`
`I
`
`
`■
`■
`■
`■
`■
`■
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`
`
`■
`
`
`
`
`
`
`
`
`
`
`
`
`■
`
`
`
`
`
`
`
`
`
`
`BY MS. PATEL:
`
` Q. Is the PFS easier to use than the vial?
`
` MR. DAVIS: Object to form. Beyond the
`
`scope. I'm sorry, just object to form.
`
` THE WITNESS: Easier to use? Can you
`
`clarify by -- by whom that you're referring to?
`
`BY MS. PATEL:
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.0011
`Regeneron v. Novartis, IPR2021-00816
`
`
`
` Chris Simms
`
`CONFIDENTIAL BUSINESS INFORMATION
`SUBJECT TO PROTECTIVE ORDER
`
`12/4/2020
`Page 74
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. Physicians?
`
` A. We believe so, yes.
`
` Q. Does the PFS require fewer steps to
`
`administer the drug?
`
` A. The prefilled syringe requires fewer steps
`
`to prepare the drug for administration, yes.
`
` Q. Do fewer steps mean less opportunity to
`
`inadvertently introduce foreign particles into the
`
`eye?
`
` MR. DAVIS: Object to form.
`
` THE WITNESS: I think some assume and
`
`presume that, thereby implying potentially a safety
`
`benefit. I'm not aware of any data that
`
`substantiates that.
`
`BY MS. PATEL:
`
` Q. So you don't assume that?
`
` MR. DAVIS: Objection.
`
`BY MS. PATEL:
`
` Q. Correct?
`
` MR. DAVIS: Misstates prior testimony.
`
` THE WITNESS: I do assume that fewer steps
`
`are a good thing for a number of reasons. I cannot
`
`~7 Trustpoint.One Alderson.
`
`www.trustpoint.one
`www.aldersonreporting.com
`
`800.FOR.DEPO
`(800.367.3376)
`
`Novartis Exhibit 2272.0012
`Regeneron v. Novartis, IPR2021-00816
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
